Last updated: February 15, 2026
Drug Overview
NDC 51672-2080 corresponds to Zepzelca (lurbinectedin), a chemotherapy agent approved by the FDA in June 2020 for the treatment of metastatic small cell lung cancer (SCLC) that has progressed on or after platinum-based chemotherapy.
Market Landscape
Indication: Advanced small cell lung cancer (SCLC), particularly in the second-line setting.
Competitive Landscape:
- Top competitors include agents like topotecan and chemotherapy combinations, with emerging options from immuno-oncology drugs such as pembrolizumab and atezolizumab, which are approved for first-line SCLC but have limited use in second-line after progression.
- Market penetration remains limited due to the recent approval and modest clinical adoption. Gilead Sciences developed Zepzelca, which is positioned as an alternative to chemotherapy for relapsed SCLC.
Market Size & Potential
- Incidence: Approximately 30,000 new cases of SCLC annually in the U.S. (source: SEER [1]).
- Second-line treatment share: About 50-60% of first-line SCLC cases relapse, making an estimated 15,000–18,000 patients eligible for second-line therapies annually.
- Market adoption: Estimated that Zepzelca may target 20%–30% of these patients within five years, contingent on clinical efficacy and physician acceptance.
Pricing and Revenue Projections
Initial Pricing:
- NDC 51672-2080 (Zepzelca) is priced at approximately $11,000 per 20 mg dose (unit price varies depending on dosage and insurance negotiation).
- Dosing is typically 3.2 mg/m^2 every three weeks, translating into an average per-treatment cost of approximately $50,000 to $70,000 per patient.
| Revenue Estimates (2023–2027): |
Year |
Estimated Patients Treated |
Market Penetration |
Total Sales (USD) |
Assumptions |
| 2023 |
1,500 |
10% |
$75 million |
Early adoption, conservative estimate |
| 2024 |
3,000 |
15% |
$150 million |
Growing familiarity, expanding indications |
| 2025 |
4,500 |
20% |
$250 million |
Increased physician adoption |
| 2026 |
6,000 |
25% |
$375 million |
Broader payer coverage |
| 2027 |
7,500 |
30% |
$525 million |
Optimized utilization |
Price Drivers & Risks
- Insurance reimbursement policies impact net pricing; high-cost drugs face potential formulary restrictions.
- Market competition from emerging therapies or repositioned chemotherapies could diminish market share.
- Clinical efficacy comparisons with standard chemotherapy and immunotherapy influence adoption.
- Regulatory developments, including potential expanded indications or line of therapy approvals, can alter pricing strategies.
Key Factors Influencing Future Pricing
- Market penetration depends on the robustness of clinical data and physician familiarity.
- Pricing adjustments may occur if new competitors gain approval or if payer negotiations result in discounts.
- Potential biosimilar or generics are unlikely due to the novelty and patent protections of Zepzelca.
Conclusion
Zepzelca presents moderate revenue potential driven by its niche application in relapsed SCLC. Initial yearly sales are projected to reach approximately $75 million in 2023, with growth contingent on market adoption and competitive dynamics. Price points are aligned with other chemotherapies but could face pressure from payers and emerging treatments.
Key Takeaways
- NDC 51672-2080 (Zepzelca) is a second-line treatment for SCLC with an initial FDA approval in 2020.
- The U.S. market for second-line SCLC therapies offers an estimated 15,000–18,000 patient opportunities annually.
- Pricing averages around $11,000 per dose, with total treatment costs circa $50,000–$70,000.
- Projected sales grow from $75 million in 2023 to over $500 million by 2027, assuming increasing adoption.
- Market penetration hinges on clinical outcomes, payer policies, and competition.
FAQs
1. What are the primary competitive drugs to Zepzelca in the treatment of relapsed SCLC?
Topotecan is the principal competing chemotherapy agent approved for second-line SCLC. Immunotherapy combinations like atezolizumab with chemotherapy are used in first-line settings but are less directly comparable.
2. How might expanded indications influence Zepzelca's market value?
Approval for earlier lines or additional indications would increase the target patient population, potentially doubling or tripling sales estimates depending on the scope of expansion.
3. What are the reimbursement challenges for Zepzelca?
High drug costs may result in formulary restrictions or prior authorization requirements; payer negotiations will dictate net prices and penetration.
4. How does Zepzelca compare price-wise to other chemotherapies?
Its per-dose cost is comparable to other chemotherapies, typically between $10,000–$15,000. The total treatment cost is similar or slightly higher, reflecting dosing schedules and patient weight variations.
5. What factors could accelerate market adoption?
Robust clinical data demonstrating superior efficacy over existing therapies, positive regulatory updates, and favorable payer coverage terms can enhance uptake.
References
[1] SEER Program, "Cancer Stat Facts: Small Cell Lung Cancer," National Cancer Institute, 2022.
